TFO
IOVA icon

Tarbox Family Office’s Iovance Biotherapeutics IOVA Stock Holding History

Tarbox Family Office’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-106
Closed -$3K – 1148
2021
Q3 		$3K Buy
+106
New +$2.5K ﹤0.01% 804

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tarbox Family Office's IOVA Position: Q4 2021 in Review

Tarbox Family Office sold out of Iovance Biotherapeutics (IOVA) in Q4 2021, closing a stake of 106 shares — an estimated $3K sold.

Tarbox Family Office first reported a position in IOVA in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

  • Tarbox Family Office reported no remaining Iovance Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Tarbox Family Office sold 106 Iovance Biotherapeutics shares in Q4 2021, an estimated $3K.
  • Tarbox Family Office first reported a position in Iovance Biotherapeutics in Q3 2021 and held it in 1 quarter.
  • Tarbox Family Office's Iovance Biotherapeutics position peaked at $3K in Q3 2021.
  • 246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on Tarbox Family Office's 13F filing for Q4 2021, filed 6 Jan 2022.